Abstract 444P
Background
In 2017, SURC was introduced in Victoria Australia responding to broader contexts challenges within the health system. SURC’s a nurse led model of care addressing and identifying gaps within an oncology service to support patients experiencing SACT toxicities during the period of active treatment. In May 2020 the Symptom & Urgent Review Clinic (SURC) commenced in Ballarat’s Regional Integrated Cancer Centre. (BRICC) provides health care in the Victorian Grampians Region covering 48,646 square kilometre area. BRICC provides three outreach cancer services to Stawell, Horsham, and Maryborough.
Methods
SURC provides a streamlined process for Oncology patients receiving SACT access to dedicated oncology nursing and medical staff through a single point of access. Patients access SURC from start of treatment, throughout their SACT and 12 weeks after treatment completion. SURC contacts all C1D5 patients, patients discharged from hospital, and shared medical/nursing model of care. SURC referrals were from the medical and nursing oncology team, allied health and other internal and external stakeholders. Patients or their carer could call SURC directly. Workforce challenges in 2022 resulted in SURC setting up a mirrored service supporting BRICC patients in Stawell and Maryborough enabling them to continue having treatment close to home and have their symptoms and toxicities addressed in a timely fashion by an advanced oncology nurse. SURC also became the point of contact for any COVID-related questions and management of patients testing COVID positive.
Results
From May 2020-April 2023 there was 6558 contacts to SURC including telephone calls, clinic presentations, same day ED and day admissions. SURC funding was outpatient WASE 40.52 data activity recorded by IBA. Pre and post SURC data for admitted patients was analysed showing inpatient stay days halved from 686 to 399, reduction in inpatient oncology visits of 104 to 70, as well as readmissions from 4-0.
Conclusions
SURC has improved quality of care and access to specialist nursing and medical advice for patients receiving SACT. SURC provides a single point of access for patients receiving SACT and has also had a significant positive impact on early symptom recognition and management in a timely manner.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Grampians Health Ballarat.
Funding
Has not received any funding.
Disclosure
S. Bartlett: Non-Financial Interests, Personal and Institutional, Member of Board of Directors: CNSA.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract